Erratum to: PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.

BMC Neurol

Avanir Pharmaceuticals, Inc., Aliso Viejo, CA, USA.

Published: September 2016

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010732	PMC
http://dx.doi.org/10.1186/s12883-016-0679-z	DOI Listing

Publication Analysis

erratum prism

prism open-label

open-label study

study assess

assess effectiveness

effectiveness dextromethorphan/quinidine

dextromethorphan/quinidine pseudobulbar

pseudobulbar affect

affect patients

patients dementia

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!